NVSNovartis AG
Price
+20%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, no red flags, price roughly fair, growing in the filings, the market undecided.
Novartis is an innovative medicines company, engaged in the research, development, manufacturing, distribution, marketing and sale of a broad range of pharmaceutical products. Our purpose is to reimagine medicine to improve and extend people’s lives. Our strategy is to deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. To support our strategy, we have clear focus areas where we commit most of our time, energy and resources.
In the company’s own words · 20-F filed Feb 4, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Novartis AG (NVS) reported revenue of $27.2B in H2 2025 (quarter ended Dec 31, 2025), up 118% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $6.34B (23% of revenue). For the full year FY2025, revenue was $54.5B (+8.4% year on year) and net income $14.0B.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, General
Ranks #2 of 7 by RyuScore